The coronavirus vaccine pioneered by biotech company Moderna, in partnership with the National Institutes of Health, has produced antibodies in all its Phase 1 trial participants, according to data published in the New England Journal of Medicine.
The goal of the early phase of the study was to gauge the vaccine's safety. Despite mild to moderate side effects in the 45 participants, it's been deemed safe to move onto the next research phase, which will include a wider range of participant age groups and health profiles.
STAT senior writer Matthew Herper is covering the story and joins host Tonya Mosley to talk about the significance of the research and the road forward on the quest for a coronavirus vaccine.
This segment aired on July 15, 2020.